Food and Chemical Toxicology 47 (2009) 2790–2797

Contents lists available at ScienceDirect

Food and Chemical Toxicology

journal homepage: www.elsevier.com/locate/foodchemtox

Quantitative HPLC analysis of two key flavonoids and inhibitory activities against aldose reductase from different parts of the Korean thistle, *Cirsium maackii*

Hyun Ah Jung [a], Yeong Shik Kim [b], Jae Sue Choi [a,c,*]

[a] Division of Food Science and Biotechnology, Pukyong National University, Busan 608-737, Republic of Korea
[b] Department of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 151-742, Republic of Korea
[c] Blue-Bio Industry RIC, 995 Eomgwangno Busanjin-gu, Busan 614-714, Republic of Korea

ARTICLE INFO

Article history:
Received 9 June 2009
Accepted 31 August 2009

Keywords:
Cirsium maackii
Thistle
Luteolin 5-*O*-β-D-glucopyranoside
Antioxidant
Diabetic complication
HPLC quantitative analysis

ABSTRACT

Previously, the correlation between antioxidant activity and HPLC profiles of several Korean thistles has been recognized. In our ongoing study of the comparative evaluation of Korean thistles, we chose *Cirsium maackii* to assess the antioxidant and aldose reductase (AR) inhibitory activities of its varying parts, including the leaves, roots, stems, and flowers, along with two major components, luteolin 5-*O*-β-D-glucopyranoside (**1**) and the aglycone luteolin (**2**). In order to determine selective and efficient usage of the individual parts, HPLC quantitative analysis of the two key flavonoids of each *C. maackii* part has been performed for the first time. From the results of the comparative evaluation between the oxidative stress-related diabetic complications and quantitative phytochemical analysis from various parts of *C. maackii*, the content of **1** and **2** might contribute to the antioxidant and AR inhibitory activities of this thistle, clearly suggesting their potential for use in the development of therapeutic or preventive agents for diabetic complications and oxidative stress-related diseases. Furthermore, our present study will pave the way of the guidelines for the efficacy and differentiation and standardization of individual parts of this herbal material, and as such, this bioactive thistle could serve as an alternative source of **1** and **2**.

© 2009 Elsevier Ltd. All rights reserved.

1. Introduction

The thistle comprises a variety of the genera, including *Carduus*, *Cirsium*, and *Silybum*. Among them, milk thistle (*Silybum marianum*), has been very intriguing to numerous researchers and pharmaceutical companies in view of the fact that this medicinal plant is a rich source of the active components silymarin and silibinin, harboring various bioactivities directed towards various hepatic diseases (Pradhan and Girish, 2006; Wu et al., 2009), along with anti-cancer (Singh and Agarwal, 2004), antioxidant (Wallace et al., 2008), neuroprotective (Nencini et al., 2007), and anti-diabetic activities (Detaille et al., 2008; Velussi et al., 1997).

Likewise, *Cirsium maackii*, a member of the Asteraceae family, is a perennial thistle that grows abundantly in Korea. The plant can attain a height of 50–100 cm, and its upright stems are covered with white feathers. Its leaves are oblong, with sharp needles, and are 15–30 cm long and 6–15 cm wide. It exhibits reddish-purple flowers, 3–5 cm in diameter, and blooms between June and August (Lee, 2002). In particular, the roots or whole plants of *Cirsium* species (Cirsii Radix et Herba) have been used as a folk medicine in the treatment of hemorrhaging, inflammation of the liver and kidney, and a variety of abdominal and intestinal disorders (Kim, 1997). The *Cirsium* species have also been determined to exert various kinds of bioactivities, including antimicrobial (Nazaruk and Jakoniuk, 2005), anti-diabetic (Perez et al., 2001), antioxidant (Jeong et al., 2008; Yoo et al., 2008), hepatoprotective (Yoo et al., 2008; Park et al., 2004; Ku et al., 2008), anti-inflammatory (Lim et al., 2008), vasorelaxant (Kim et al., 2008), and anti-cancer activities (Liu et al., 2007). In addition, numerous phytochemicals, including flavonoids, phenolic acids, lignans, polyacetylenes, acetylenes, sterols, triterpenes, sesquiterpene lactones, and alkaloids have been thus far isolated from these species (Jeong et al., 2008; Jordon-Thaden and Louda, 2001; Lee et al., 1994; Yim et al., 2003; Chung et al., 2002).

Since the *Cirsium* and *Silybum* genera that belong to the thistle, exhibit similar bioactivities, including hepatoprotective and

Abbreviations: AR, aldose reductase; ARIs, aldose reductase inhibitors; DCF, 2,7-dichlorodihydrofluorescein; DCFH-DA, 2′,7′-dichlorodihydrofluorescein diacetate; DTPA, diethylenetriaminepentaacetic acid; DHR 123, dihydrorhodamine 123; DMSO, dimethylsulfoxide; DPPH, 1,1-diphenyl-2-picrylhydrazyl; EDTA, ethylenediaminetetraacetic acid; HRAR, human recombinant aldose reductase; LPS, lipopolysaccharide; .OH, hydroxyl radical; NADH, nicotinamide adenine dinucleotide; NADPH, nicotinamide adenine dinucleotide phosphate; $ONOO^-$, peroxynitrite; PMSF, phenylmethylsulfonylfluoride; RLAR, rat lens aldose reductase; ROS, reactive oxygen species.

* Corresponding author. Address: Division of Food Science and Biotechnology, Pukyong National University, Busan 608-737, Republic of Korea. Tel.: +82 51 629 5845; fax: +82 51 629 5842.
E-mail address: choijs@pknu.ac.kr (J.S. Choi).

0278-6915/$ - see front matter © 2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.fct.2009.08.014

antioxidant activities, and are thus consumed as hepatoprotective agents, and the best-known groups of their secondary metabolites are flavonoids, *C. maackii* was elected to develop promising inhibitory agents with aldose reductase (AR) through comparative evaluation between the bioactivity potential and the quantitative HPLC studies. The antioxidant capacities were determined by the 1,1-diphenyl-2-picrylhydrazyl (DPPH), peroxynitrite ($ONOO^-$), hydroxyl radical (·OH), and total reactive oxygen species (ROS) assays, and the AR inhibition potential was determined by the rat lens AR (RLAR) and human recombinant AR (HRAR) assays. The quantitative HPLC experiments of two major isolated flavonoids, luteolin 5-*O*-β-D-glucopyranoside (**1**) and its aglycone luteolin (**2**) in the individual parts were performed for the first time, offering valuable information on part-specific preponderance of active constituents in this thistle. The relationships between the contents of **1** and **2**, and the intensity of their antioxidant and AR inhibitory activities, were also assessed in this study. Considering the results of these above experiments, we will evaluate the possibility of this Korean thistle as not only a therapeutic or preventive agent for diabetic complications and oxidative stress-related diseases, but also a rich source of **1** and **2**.

2. Materials and methods

2.1. General

The ^{1}H and ^{13}C NMR spectra were determined using a JEOL JNM ECP-400 spectrometer (400 MHz for ^{1}H NMR and 100 MHz for ^{13}C NMR) in dimethylsulfoxide (DMSO)-d_6. The chemical shifts were referenced to residual solvent peaks (2.49 ppm for ^{1}H NMR and 39.50 ppm for ^{13}C NMR). Column chromatography was performed using silica (Si) gel 60 (70–230 mesh, Merck, Germany), and TLC was conducted on precoated Merck Kieselgel 60 F_{254} plates (20 × 20 cm, 0.25 mm), using 50% H_2SO_4 as a spray reagent.

2.2. Chemicals and reagents

DPPH, L-ascorbic acid, L-2-amino-3-mercapto-3-methylbutanoic acid (L-penicillamine), phenylmethylsulfonylfluoride (PMSF), ethylenediaminetetraacetic acid (EDTA), nicotinamide adenine dinucleotide phosphate (NADPH), DL-glyceraldehyde dimer, and diethylenetriaminepentaacetic acid (DTPA) were purchased from Sigma Chemical Co (St. Louis, MO, USA). 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) was obtained from Aldrich Chemical Co. (Milwaukee, WI, USA). 2′,7′-Dichlorodihydrofluorescein diacetate (DCFH-DA) and dihydrorhodamine 123 (DHR 123) were of high quality and were purchased from Molecular Probes (Eugene, OR, USA), and $ONOO^-$ from Cayman Chemicals Co. (Ann Arbor, MI, USA). HRAR (0.4 unit) was purchased from Wako Chemicals (Osaka, Japan). All chemicals and solvents used were purchased from E. Merck, Fluka, and Sigma and Aldrich Co., unless stated otherwise.

2.3. Plant materials

Whole plants of *C. maackii* were collected in Ulsan, Republic of Korea, in August 2001. This plant was authenticated by specialist of *Cirsium* taxonomy, Dr. Y. Kadota at Department of Botany, National Museum of Nature and Science in Tsukuba, Japan. Each of whole plant was collected, followed by separating into flowers, leaves, roots, and stem and then dried in the shade for a week. A voucher specimen as a whole plant registered and deposited at the herbarium of National Museum of Nature and Science in Tsukuba, Japan as well as the Division of Food Science and Biotechnology, Pukyong National University (Professor Choi, J.S.).

2.4. Extraction, fractionation, and isolation of C. maackii

The dried leaves (1.28 kg) were extracted with hot MeOH (2.5 l × 3 times). After filtration, the MeOH extract (316.3 g) was obtained *via in vacuo* concentration at 40 °C. The MeOH extract (310 g) was then dissolved with a mixture of CH_2Cl_2:MeOH:H_2O (10:1:9), after which the CH_2Cl_2 soluble fraction was concentrated to yield a CH_2Cl_2 fraction (68.8 g). The aqueous fraction was successively partitioned to yield the EtOAc (80.6 g), *n*-BuOH (30.7 g), and H_2O soluble fractions (125.8 g). Repeated column chromatography of the EtOAc fraction (80.6 g) from the leaves extract with a mixture solvent of CH_2Cl_2 and MeOH (20:1–1:1, gradient) can afford **1** (23.25 g) and **2** (10.76 g) (Scheme 1). The roots, flowers, and stems were extracted and fractionated *via* procedures identical to those employed with the leaves, and the yields of each of the fractions are shown in Table 1. Two isolated flavonoids (**1** and **2**) were then identified by comparisons with published spectral data (Agrawal, 1989), as well as TLC and HPLC analysis.



Scheme 1. Extraction, fractionation, and isolation of *C. maackii* leaves.

2.4.1. Luteolin 5-O-β-D-glucopyranoside (1)

^{1}H NMR (400 MHz, DMSO-d_6) δ: 10.97, 9.83, 9.39 (aromatic OH), 7.38 (1H, dd, *J* = 9.0, 2.0 Hz, H-6), 7.36 (1H, d, *J* = 2.0 Hz, H-2), 6.88 (1H, d, *J* = 9.0 Hz, H-5), 6.79 (1H, d, *J* = 2.2 Hz, H-8), 6.70 (1H, d, *J* = 2.2 Hz, H-6), 6.55 (1H, s, H-3), 4.71 (1H, d, *J* = 7.3 Hz, Glucose H-1), 3.76 (1H, dd, *J* = 13.0, 2.1 Hz, Glucose H-6a), 3.55 (1H, m, Glucose H-5), 3.54 (1H, m, Glucose H-6b), 3.49 (1H, s, Glucose H-3), 3.30 (1H, s, Glucose H-4), 3.20 (1H, s, Glucose H-2). ^{13}C-NMR (100 MHz, DMSO-d_6) δ: 176.95 (C-4), 162.59 (C-2), 161.37 (C-7), 158.68 (C-5), 158.32 (C-9), 149.26 (C-4), 145.69 (C-3), 121.52 (C-6), 118.56 (C-1), 116.01 (C-5), 113.12 (C-2), 108.25 (C-10), 105.70 (C-3), 104.52 (C-1″), 104.33 (C-6), 98.20 (C-8), 77.56 (C-3″), 75.62 (C-5″), 73.65 (C-2″), 69.70 (C-4″), 60.86 (C-6″).

2.4.2. Luteolin (2)

^{1}H-NMR (400 MHz, DMSO-d_6) δ: 12.97 (5-OH), 10.82, 9.92, 9.41 (aromatic OH), 7.41 (1H, dd, *J* = 9.4, 2.2 Hz, H-6), 7.39 (1H, d, *J* = 2.2 Hz, H-2), 6.88 (1H, d, *J* = 9.4 Hz, H-5), 6.66 (1H, s, H-3), 6.44 (1H, d, *J* = 2.2 Hz, H-8), 6.18 (1H, d, *J* = 2.2 Hz, H-6). ^{13}C-NMR (100 MHz, DMSO-d_6) δ: 181.63 (C-4), 164.10 (C-2), 163.88 (C-7), 161.46 (C-5), 157.27 (C-9), 149.67 (C-4), 145.72 (C-3), 121.52 (C-6), 118.97 (C-1), 116.00 (C-5), 113.36 (C-2), 103.70 (C-10), 102.86 (C-3), 98.82 (C-6), 93.82 (C-8).

2.5. HPLC quantitative analysis

Reverse-phase HPLC was performed on the JASCO HPLC system (Tokyo, Japan), consisting of PU-1580 Intelligent HPLC pump, LG-1580–04 quaternary gradient unit, UV-1575 intelligent UV/Vis detector, PG-1580–54 4-line degasser, and CO-1560 intelligent column thermostat. The BORWIN chromatographic system (Le Fontanil, France) was used for HPLC data analysis. In order of chromatographic separation, we accomplished on a Phenomenex C18 reverse phase column (Phenomenex, 4.6 × 250 mm, 5 μm) at 25 °C and monitored at 340 nm. A linear gradient solvent system consisted of 0.5% phosphoric acid in water (solvent A) and 100% methanol (solvent B) and changed from 75% (solvent A):25% (solvent B) to 0% (solvent A) and 100% (solvent B) for 60 min at the flow rate of 0.5 ml/min. For preparation of stock solutions, extracts and two flavonoids were dissolved in 100% MeOH at concentrations of 4 mg/ml, and 2 mg/ml, respectively. After filtration through a centrifugal filter device (0.45 μm, Millipore Co., Bedford, MA, USA), 10 μl of each sample was injected. The retention times of **1** and **2** were approximately 27.40 min and 40.50 min, respectively. The calibration curves of **1** and **2** were drawn with five standards at concentrations ranging from 10 to 500 μg/ml. The regression equations were calculated in the form of $y = ax + b$, where y and x correspond to the peak area and concentration, respectively. The regression equations and correlation coefficients (r^2) of **1** and **2** are as follows: $y = 25267x + 831222$, $r^2 = 0.9959$ for **1**; $y = 53168x + 193400$, $r^2 = 0.9975$ for **2**. The relative quantity of two flavonoids in the MeOH extracts (mg/g of the extract) was calculated from each equation.

2.6. Evaluation of bioactivities

2.6.1. Assay for DPPH radical scavenging activity

According to the modified method, which was first employed by Blois (1958), the DPPH radical scavenging activity was evaluated. Briefly, a 160 (µl) of methanolic solution of various sample (final concentration (f.c.) of 320 µg/ml for extract, fractions, and flavonoids) was added to 40 µl DPPH methanolic solution (1.5×10^{-4} M). After vortexing thoroughly and leaving for 30 min at room temperature, the optical density was measured at 520 nm using a microplate reader spectrophotometer VERSAmax (Molecular Devices, CA, USA). L-Ascorbic acid was employed as a positive control. The DPPH radical scavenging activity of each sample was expressed in terms of IC_{50} (µg/ml required to scavenge DPPH free radicals by 50%) and calculated from the log–dose inhibition curve.

2.6.2. Assay for $ONOO^-$ scavenging activity

$ONOO^-$ scavenging activity was assessed by the modified Kooy's method (Kooy et al., 1994), which involved the monitoring of highly fluorescent rhodamine 123, which was rapidly produced from non-fluorescent DHR 123 in the presence of $ONOO^-$. In brief, the rhodamine buffer (pH 7.4) consisted of 50 mM sodium phosphate dibasic, 50 mM sodium phosphate monobasic, 90 mM sodium chloride, 5 mM potassium chloride, and 100 µM DTPA. The final DHR 123 concentration was 5 µM. The buffer in this assay was prepared prior to use and placed on ice. The samples were dissolved in 10% DMSO (f.c. 100 µg/ml for the extracts/fractions and 10 µg/ml for the isolated flavonoids). The background and final fluorescent intensities were measured 5 min after treatment with and without the addition of authentic $ONOO^-$ (10 µM), dissolved in 0.3 N sodium hydroxide. The fluorescence intensity of the oxidized DHR 123 was evaluated using a microplate fluorescence reader FL 500 (Bio-Tek Instruments Inc., Winooski, VT, USA) at excitation and emission wavelengths of 480 and 530 nm, respectively. $ONOO^-$ scavenging activity values were calculated as the final fluorescence intensity minus the background fluorescence, *via* the detection of DHR 123 oxidation. L-Penicillamine was employed as a positive control.

2.6.3. Assay for the total ROS inhibitory activity

ROS generation was assessed using the ROS-sensitive fluorescence indicator DCFH-DA (Lebel and Bondy, 1990). The kidney or liver homogenates of lipopolysaccharide (LPS)-treated rats injected (5 mg/kg, intraperitoneal injection) were used as the total ROS sources. Following the guidelines of Aging Tissue Bank at Pusan National University (Busan, Republic of Korea), male Wistar rats weighing 150–200 g were sacrificed by decapitation and the kidneys were quickly removed and rinsed in iced cold-buffer [100 mM Tris, 1 mM EDTA, 0.2 mM PMSF, 1 µM pepstatin, 2 µM leupeptin, 80 mg/l trypsin inhibitor, 20 mM β-glycerophosphate, 20 mM NaF, 2 mM sodium orthovanadate (pH 7.4)]. The kidney tissues were immediately frozen in liquid nitrogen, and stored at −80 °C. Ten microliter of each test sample (f.c. 40 µg/ml for the extracts/fractions and 10 µg/ml for the isolated flavonoids) was added to 190 µl of kidney postmitochondrial fraction in a 50 mM potassium phosphate buffer. Then, the mixtures were loaded with 50 µl of DCFH-DA (12.5 mM) in a potassium phosphate buffer and shaken for 5 min. Finally, the fluorescence of 2,7-dichlorodihydrofluorescein (DCF), the oxidation product of DCFH-DA was measured on a microplate fluorescence spectrophotometer (Bio-Tek Instruments, Inc., Winooski, VT, USA) for 30 min at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. The percent inhibition (%) was obtained by the following equation: $\% \text{ Inhibition} = [1 - (S_{30\text{min}} - S_{5\text{min}})/(C_{30\text{min}} - C_{5\text{min}})] \times 100$, where C_{30} was the fluorescence of the control (enzyme, buffer, and substrate) after 30 min of incubation, $C_{5\text{min}}$ was the initial fluorescence of the control, S_{30} was the fluorescence of the tested samples (enzyme, sample solution, and substrate) after 30 min of incubation, and $S_{5\text{min}}$ was the initial fluorescence of the tested samples. Trolox was used as a positive control.

2.6.4. Assay for ·OH inhibitory activity

The crude extracts and fractions at a concentration of 40 µg/ml were added to 1 mM H_2O_2 and 0.2 mM $FeSO_4$, and incubated at 37 °C for 5 min. Then esterase-treated 2 µM DCFH-DA was added and the changes in fluorescence intensity were monitored on a microplate fluorescence spectrophotometer (Bio-Tek Instruments Inc., Winooski, VT, USA), with excitation and emission wavelengths at 460 and 530 nm, respectively (Jo et al., 2006). The percent inhibition (%) was obtained by the same equation as mentioned in the total ROS assay. Trolox was employed as a positive control.

2.6.5. Assay for RLAR inhibitory activity

Rat lens homogenates were used as AR sources. In the experiment, we followed the Guidelines for Care and Use of Laboratory Animals as approved by Pukyong National University (Busan, Republic of Korea). According to the modified method of Hayman and Kinoshita (1965), rat lens homogenate was prepared. Briefly, the lens were removed from the eyes of Sprague–Dawley rats (Samtako BioKorea, Inc.) weighing 250–280 g. The rat lens were homogenized in sodium phosphate buffer (pH 6.2). The supernatant was obtained by centrifugation of the homogenate at 10,000 rpm at 4 °C for 20 min and was frozen until use. A crude AR, with a specific activity of 6.5 U/mg, was used in the evaluations for enzyme inhibition. The partially purified material was separated into 1.0 ml aliquots, and stored at −80 °C. Each 1.0 ml cuvette contained equal units of enzyme, 100 mM sodium phosphate buffer (pH 6.2), and 1.6 mM NADPH, both with and without 50 mM of the substrate, DL-glyceraldehyde, and an inhibitor (f.c. 10 µg/ml for the extract, and 100 µM for the isolated flavonoids, dissolved in 100% DMSO). The final concentration of DMSO is 1%. The AR activity was determined by measuring the decrease in NADPH absorption at 340 nm over a 4 min period on a Ultrospec®2100pro UV/Visible spectrophotometer with SWIFT II Applications software (Amersham Biosciences, New Jersey, USA). Quercetin and epalrestat, well known aldose reductase inhibitors (ARIs) were used as positive controls. The inhibition percentage (%) was calculated as $[1 - (\Delta A \text{ sample/min} - \Delta A \text{ blank/min})/(\Delta A \text{ control/min} - \Delta A \text{ blank/min})] \times 100$, where ΔA sample/min represents the reduction of absorbance for 4 min with the test sample and substrate, respectively, and ΔA control/min represents the same, but with 100% DMSO instead of a sample.

2.6.6. Assay for HRAR inhibitory activity

The HRAR inhibitory activities were examined according to the method of Nishimura et al. (1991). The reaction mixture was prepared as follows: 100 µl of 0.15 mm NADPH, 100 µl of 10 mM DL-glyceraldehyde, as a substrate, 5 µl of the HRAR, and various concentrations of the samples in a total volume of 1.0 ml of 100 mM sodium phosphate buffer (pH 6.2). The AR activity was determined by measuring the decrease in NADPH absorption at 340 nm over a 1 min period on an Ultrospec®2100pro UV/Visible spectrophotometer with SWIFT II Applications software (Amersham Biosciences, New Jersey, USA). Quercetin and epalrestat, well known ARIs were used as positive controls. The inhibition percentage (%) was calculated similar to the RLAR assay, except that ΔA sample/min represents the reduction of absorbance for 1 min with the test samples and substrate.

2.6.7. Statistics

The Kruskal–Wallis test and the Mann–Whitney *U* test were used to determine the statistical significance of differences between values for various experimental and control groups. Data were expressed as the mean ± SEM in triplicate.

3. Results

3.1. Antioxidant capacities of different parts of C. maackii

As summarized in Table 1, and Figs. 1 and 2, characterization of the antioxidant activities of the MeOH extracts was attempted, along with the CH_2Cl_2, EtOAc, *n*-BuOH, and H_2O fractions of the flowers, leaves, roots, and stems of *C. maackii*, using the *in vitro* DPPH free radical and authentic $ONOO^-$ scavenging assays, as well as the ·OH and total ROS inhibitory assays. As shown in Table 1, differences were noted in the antioxidant potentials of the crude MeOH extracts among the tested assays, depending on the part of the thistle assayed. The IC_{50} values of the DPPH radical scavenging capacity increased in the following order: roots (10.2 µg/ml); stems (11.9 µg/ml); flowers (51.9 µg/ml); leaves (84.9 µg/ml), as compared with a positive control, L-ascorbic acid (IC_{50} 0.8 µg/ml). However, the $ONOO^-$ scavenging activity of the leaves (IC_{50} 1.78 µg/ml) was significantly more profound than observed for other components of the plant, including the stems (IC_{50} 8.27 µg/ml), roots (IC_{50} 8.81 µg/ml), and flowers (IC_{50} 11.27 µg/ml). As illustrated in Table 1, the IC_{50} values for the total ROS inhibition of the crude extracts were demonstrated, an order identical to that of the $ONOO^-$ assay: leaves (3.46 µg/ml); stems (8.13 µg/ml); roots (17.36 µg/ml); flowers (33.42 µg/ml). In particular, the MeOH extract of the leaves had substantial antioxidant activity, comparable with that of the positive controls, L-penicillamine (IC_{50} 2.60 µg/ml) in the $ONOO^-$ assay, and Trolox (IC_{50} 7.24 µg/ml) in the total ROS assay (Table 1). Among the several solvent soluble fractions obtained from different parts of the plant, the EtOAc and *n*-BuOH fractions had excellent antioxidant potential with IC_{50} values of 3.4–17.1 µg/ml for the DPPH assay (a positive control, L-ascorbic acid, IC_{50} 0.8 µg/ml), and with IC_{50} values of 0.85–5.80 µg/ml for the $ONOO^-$ assays (a positive control, L-penicillamine, IC_{50} 2.60 µg/ml) (Table 1). The EtOAc fraction obtained from all parts of the *C. maackii* also had predominant and concentration-dependent inhibitory activities with IC_{50} values ranging from 0.59 to 2.47 µg/ml, comparable to that of the positive control, Trolox (IC_{50} 7.24 µg/ml), in the total ROS assay (Table 1 and Fig. 1). In

Table 1
Antioxidant activities of different parts of *C. maackii* in DPPH, $ONOO^-$ and total ROS assays.

Parts	Fractions	Yield[a]	DPPH[b]	$ONOO^{-}$[c]	Total ROS[d]
Flowers	MeOH	9.17	51.9	11.27 ± 0.24	33.42 ± 0.95
	CH_2Cl_2	60.20	>320	13.94 ± 0.19	>40
	EtOAc	5.70	17.1	1.37 ± 0.10	1.79 ± 0.14
	n-BuOH	11.90	12.8	2.09 ± 0.04	7.33 ± 0.86
	H_2O	20.16	78.4	12.13 ± 0.13	>40
Leaves	MeOH	24.71	84.9	1.78 ± 0.07	3.46 ± 0.20
	CH_2Cl_2	21.75	294.9	>100	>40
	EtOAc	25.48	6.8	5.80 ± 0.04	0.59 ± 0.01
	n-BuOH	9.71	5.9	1.49 ± 0.05	13.22 ± 1.48
	H_2O	39.77	83.9	9.41 ± 0.52	>40
Roots	MeOH	16.21	10.2	8.81 ± 0.34	17.36 ± 0.61
	CH_2Cl_2	14.29	132.9	10.04 ± 0.33	>40
	EtOAc	8.23	3.4	0.85 ± 0.03	2.47 ± 0.27
	n-BuOH	14.38	6.2	1.68 ± 0.05	9.01 ± 0.09
	H_2O	62.33	97.5	32.43 ± 0.28	>40
Stems	MeOH	14.90	11.9	8.27 ± 0.22	8.13 ± 0.29
	CH_2Cl_2	28.00	176.7	25.58 ± 0.71	25.29 ± 3.94
	EtOAc	6.89	7.9	0.41 ± 0.01	1.60 ± 0.12
	n-BuOH	11.26	9.8	1.45 ± 0.14	14.91 ± 0.41
	H_2O	52.98	53.1	21.12 ± 0.74	>40
L-Ascorbic acid[e]			0.8		
L-Penicillamine[f]				2.60 ± 0.16	
Trolox[g]					7.24 ± 0.66

[a] Yields (%) of the MeOH extracts are expressed as the crude MeOH extract weight (g) per 100 g of dried plant materials, and that of each fraction as the fractions weight (g) per 100 g of the crude MeOH extract. These values were calculated by the equation [(1 − respective weight/total weight) × 100].
[b–d] 50% inhibitory concentrations (IC_{50} μg/ml).
[e–g] Positive controls. Values were expressed as the mean ± SEM in triplicate.



Fig. 1. Concentration-dependent inhibitory activities of the EtOAc fractions of *C. maackii* on total ROS generation. Total ROS inhibitory activities of the EtOAc fractions from each part of *C. maackii* were illustrated as % inhibition of the total ROS generation at test concentrations from 0.8 to 20 μg/ml. Trolox was employed as a positive control. Values were expressed as the mean ± SEM in triplicate.

addition, the respective EtOAc and *n*-BuOH fractions had potent antioxidant activities with % inhibitions from 53.12 to 69.75, comparable to that of the positive control, Trolox (69.36%), in the ·OH assay (Fig. 2). Conversely, the CH_2Cl_2 fractions of the individual parts exhibited no activities in the ·OH assay, and most of the H_2O fractions tended to exhibit only minimal antioxidant activity. However, the H_2O fraction of the leaves manifested a significant degree of $ONOO^-$ scavenging activity with an IC_{50} value of 9.41 μg/ml and an ·OH % inhibition of 51.40 (Table 1 and Fig. 2). Considering the above antioxidant results of the extracts and fractions from the *C. maackii* flowers, leaves, roots, and stems, it can be



Fig. 2. Inhibitory activities of different parts of *C. maackii* on ·OH generation ·OH inhibitory activities of the MeOH extracts and several fractions from each part of *C. maackii* were illustrated as the inhibition (%) of ·OH generation in 1.0 mM H_2O_2 and 0.2 mM $FeSO_4$, at a concentration of 40 μg/ml. Values were expressed as the mean ± SEM in triplicate.

concluded that antioxidant principles may exist in the relatively polar fractions, including the EtOAc and *n*-BuOH fractions.

3.2. RLAR inhibitory activities of different parts of C. maackii

In order to evaluate the AR inhibitory activities, different parts of *C. maackii* were determined *via* the RLAR inhibition assay. Each part of this Korean thistle showed a concentration-dependent inhibition. As shown in Table 2, the leaf extract exerted the most potent RLAR inhibitory activity with an IC_{50} value of 0.54 μg/ml, compared with the positive control, quercetin, with an IC_{50} value of 0.22 μg/ml. The root and stem extracts followed with IC_{50} values of 2.55 and 3.22 μg/ml, respectively, then the flower with an IC_{50} value of 7.98 μg/ml. These RLAR inhibitory results coincided with the order of the $ONOO^-$ scavenging and total ROS inhibitory data.

3.3. Quantitative analysis of two active flavonoids from different parts of C. maackii

By virtue of repeated column chromatography of the EtOAc fractions from the leaves, luteolin 5-*O*-β-D-glucopyranoside (**1**) and luteolin (**2**) were obtained as major constituents in substantial

Table 2
RLAR inhibitory activities of the MeOH extract of different parts of *C. maackii*[a].

Parts	Concentration (μg/ml)	Inhibition (%)	IC_{50} (μg/ml)
Quercetin[b]	1	72.36 ± 4.84	0.22 ± 0.02
	0.2	47.96 ± 2.42	
	0.04	24.22 ± 0.18	
Flowers	10	65.48 ± 5.12	7.98 ± 0.48
	5	28.92 ± 2.17	
	1	−7.70 ± 0.98	
Leaves	5	92.49 ± 6.93	0.54 ± 0.04
	1	67.93 ± 1.24	
	0.2	36.39 ± 2.06	
Roots	10	81.34 ± 6.02	2.55 ± 0.19
	5	65.21 ± 1.71	
	1	40.88 ± 2.19	
Stems	10	84.76 ± 2.01	3.22 ± 0.43
	5	70.70 ± 3.19	
	1	31.31 ± 2.19	

[a] RLAR inhibitory activities of each part of *C. maackii* were demonstrated as% inhibition, as well as 50% inhibitory concentrations (IC_{50} μg/ml).
[b] Positive control. Values were expressed as the mean ± SEM in triplicate.



Fig. 3. HPLC chromatograms of different parts of *C. maackii*. MeOH extracts of: Flowers (A); Leaves (B); Roots (C); Stems (D). Peak 1 (Rt: 27.40 min, Luteolin-5-glucoside), peak 2 (Rt: 40.50 min, Luteolin); HPLC conditions are described in Section 2.

amounts of 23.25 g and 10.76 g, respectively (Scheme 1). In order to determine the part-specific preponderance of **1** and **2**, HPLC quantitative analysis of the *C. maackii* flowers, leaves, roots, and stems was performed (Fig. 3). The MeOH extract of the flowers had clear differences from the crude extracts obtained from other



Fig. 4. Relative content of two key flavonoids from the MeOH extracts of each part of *C. maackii*. The relative content of the two flavonoids are expressed as percentages, and calculated from the respective regression equations of standards. Values were expressed as the mean ± SEM in triplicate.

parts of the plant. The flower MeOH extract exhibited peaks smaller than those seen in the extracts of the leaves, stems, and roots, corresponding to **1** and **2** at retention times of 27.40 and 40.50 min, along with two other larger peaks at 33.27 and 43.92 min (Fig. 3A), which were confirmed to be apigenin 7-*O*-β-D-glucuronide and apigenin, respectively. In the MeOH extracts of the leaves, roots, and stems, however, the peaks corresponding to **1** and **2** were the primary peaks (Fig. 3B–D). The relative content of **1** in the flowers, leaves, roots, and stems MeOH extracts from *C. maackii* were 5.98%, 45.18%, 68.80%, and 55.12%, respectively. In the case of the leaves, the yield of the EtOAc fraction from the MeOH extract was 25.48%, indicating that the leaves might be a great source of **1** (Table 1). The contents of **2** in the flowers, leaves, roots, and stems MeOH extracts were 14.94%, 31.54%, 10.83%, and 22.79%, respectively (Fig. 4). The contents of **1** and **2** were also low in the crude flower extracts, exerting relatively weak antioxidant activities, indicating that the two flavonoids were crucial contributors to bioactivity.

3.4. Antioxidant and AR inhibitory activities of two active flavonoids

In this study we have evaluated the antioxidant and AR inhibitory properties of **1** and **2** in DPPH free radical, total ROS, $ONOO^-$, RLAR, and HRAR assays (Table 3). Our results demonstrated diverse antioxidant potentials between the DPPH radical, $ONOO^-$, and total ROS assays. Compound **1**, which harbors a glucose moiety at the 5 position, exerted antioxidant activities more potent than observed in its aglycone (**2**) in the total ROS system. Compound **1** at a concentration of 40 μg/ml, was measured to have a % inhibition of 72.33, comparable to the positive control, Trolox (72.87%). Compound **2**, however, had an activity higher than **1** in the DPPH radical and $ONOO^-$ systems. Compound **2** exhibited an $ONOO^-$ scavenging % of 73.78 at a concentration of 10 μg/ml, comparable to that of the positive control, L-penicillamine (75.08%). Also, **2** clearly possessed a DPPH radical scavenging activity with an IC_{50} value of 0.06 μM, more potent than the DPPH radical scavenging activities of the well-known antioxidant, L-ascorbic acid (IC_{50} 1.74 μM). In both AR assays, **1** and **2** exhibited outstanding AR inhibitory activities with respective IC_{50} values of 0.33 and 0.52 μM for RLAR, and 6.07 and 9.13 μM for HRAR, as compared with well-known AR inhibitors, quercetin (IC_{50} 1.53 μM for RLAR and IC_{50} 14.79 μM for HRAR) and epalrestat (IC_{50} 0.07 μM for RLAR and HRAR). In particular, **1** exerted as good an inhibitory activity as **2**, an AR inhibitor, including RLAR and HRAR (Matsuda et al., 2002; Kato et al., 2008).

Table 3
Antioxidant and Anti-AR inhibitory activities of two flavonoids from *C. maackii*.

	DPPH[a]	$ONOO^-$[b]	Total ROS[c]	RLAR[d]	HRAR[e]
1	2.56 ± 0.15	21.88 ± 1.39	72.33 ± 0.77	0.33 ± 0.00	6.07 ± 0.05
2	0.06 ± 0.01	73.78 ± 1.19	48.43 ± 0.71	0.52 ± 0.05	9.18 ± 0.10
L-Ascorbic acid[f]	1.74 ± 0.19				
L-Penicillamine[g]		75.08 ± 1.40			
Trolox[h]			72.87 ± 1.31		
Quercetin[i]				1.53 ± 0.20	14.79 ± 0.35
Epalrestat[j]				0.07 ± 0.00	0.07 ± 0.01

[a,d,e] Inhibitory (50%) concentrations (IC_{50} μM).
[b,c] % Inhibition at respective concentrations of 10 μg/ml and 40 μg/ml.
[f–j] Positive controls. Values were expressed as the mean ± SEM in triplicate.

4. Discussion

AR is a NADPH-dependent oxidoreductase, and acts as a key enzyme in the polyol pathway. Under diabetic conditions, there is excessive glucose uptake in tissues, resulting in an increased rate of the AR-related polyol pathway. Accelerating the AR-polyol mechanism augments the reduction of glucose to sorbitol, followed by nicotinamide adenine dinucleotide (NADH)-dependent sorbitol dehydrogenase-catalyzed fructose production (Kaneko et al., 2005). These excessive glucose reduction and sorbitol oxidation are reported to result in consumption and depletion of NADPH and NAD^+, leading to augmentation of cellular oxidative stress and ROS production in cells and tissues (Chung et al., 2003; Srivastava et al., 2005). Excessive free radicals, ROS and RNS, result in the oxidation of cellular molecules, proteins, lipids, and DNA, ultimately culminating in cell death or tissue injury. This phenomenon has been implicated in a variety of human degenerative phenomena, including aging, diabetes (Srivastava et al., 2005), inflammation (Azad et al., 2008), and diabetic complications (Pacher et al., 2005; Brownlee, 2001). Considering this intimate relationship between antioxidant and AR inhibitory activities, potent antioxidants might take advantage of the development of promising anti-diabetic complications agents in addition to ARIs. In particular, flavonoids have been shown to exert their antioxidant activities by virtue of both their excellent metal chelation and radical scavenging properties (Rice-Evans et al., 1996). As a result of their antioxidant and free radical scavenging activities against ROS and RNS, the flavonoids are believed to function as anti-diabetic complications agent (Jung et al., 2008a,b; Manzanaro et al., 2006; Park et al., 2004). Since antioxidant activity is highly associated with AR inhibitory activities, and flavonoids might be the key contributors to both activities, the present study on antioxidant and AR inhibitory activities of *C. maackii* was of great value.

In our consecutive research on the relevance of the phytochemical content and bioactive potency of Korean thistles, we have focused on *C. maackii*. As milk thistle is popular worldwide due to its major components that harbor various bioactivities, silymarin and silibinin, *C. maackii* might take a preponderant occupation in medicine-based natural products through their key components, luteolin 5-*O*-β-D-glucopyranoside (**1**) and luteolin (**2**).

The relative content of these two key flavonoids from different parts of *C. maackii* was verified *via* quantitative HPLC analysis for the first time (Fig. 3). In particular, **1** was isolated previously from *C. magofukui* and *C. sieboldii*, and considered to be a rare flavonoid due primarily to its stereochemical hindrance between the hydroxyl group at the 5-position and the adjacent carbonyl group at the 4-position (Iwashina et al., 1995, 1989; Harborne, 1967). Interestingly, **1** and **2** were characterized and isolated as predominant compounds from the leaves of *C. maackii* in the present study (Scheme 1). Except for the flower MeOH extract, HPLC chromatograms of the other parts of the *C. maackii* bore two identical peaks at 27.40 and 40.50 min, corresponding to **1** and **2**, respectively (Fig. 3B–D). Although **1** and **2** occurred in all parts of the *C. maackii*, there was little difference in relative content: **1** was 5.98%, 45.18%, 68.80%, and 55.12%; **2** was 14.94%, 31.54%, 10.83%, and 22.79%, in the flowers, leaves, roots, and stems, respectively (Fig. 4). Considering the yield (%) of the extracts and fractions from each part (Table 1), the leaf MeOH extract and its EtOAc fraction were expected to harbor bioactive components (**1** and **2**) in large quantities, indicating that the leaves exerted the most effective part of the antioxidant and anti-diabetic complications among various parts of *C. maackii*.

Based on our antioxidant results, the MeOH extracts and polar fractions of each part of the *C. maackii* were found to possess significant antioxidant activity. The leaves, roots, and stems exerted excellent antioxidant capacities in the $ONOO^-$ and total ROS assays, as well as predominant inhibitory activities in the RLAR assay. In particular, the EtOAc and *n*-BuOH fractions from the flowers, leaves, stems, and roots exhibited significant DPPH radical and $ONOO^-$ scavenging activities, as well as total ROS and ·OH inhibitory activities (Table 1; Figs. 1 and 2). Although all parts of the *C. maackii* exhibited good inhibitory activities against RLAR, the leaves exhibited outstanding AR inhibitory activities (Table 2). While the antioxidant capacity of **1** and **2** showed more or less difference of the intensity in respective assays, two flavonoids exhibited significant antioxidant activities and AR inhibitory activities in test assays (Table 3). The presence of an *ortho*-hydroxyl group (catechol) within the B-ring was associated with marked antioxidant activities in the DPPH, $ONOO^-$, and total ROS assays, and the presence of a hydroxyl group at the C-5 position may exert an even more significant activity in the total ROS assay than in other assays. Although studies on the inhibitory activities of the *Cirsium* species against diabetes and diabetic complications were limited, various activities of luteolin and its glycosides were reported: luteolin and its commonly occurring glycoside have been reported to possess significant antiviral, hepatoprotective (Park et al., 2004), antioxidant (López-Lázaro, 2009), anti-AR (Kato et al., 2008; Jung et al., 2007; Matsuda et al., 1995), and anti-diabetes activities (Kim et al., 2000; Reddy et al., 2005). In particular, luteolin 5-*O*-β-rutinoside was reported to possess anti-diabetes activities (Zarzuelo et al., 1996). Although there are several AR inhibitory studies on luteolin (**2**) (Kato et al., 2008), the AR inhibitory activities of luteolin 5-*O*-β-D-glucopyranoside (**1**) and *Cirsium* species *via* the RLAR and HRAR assays were revealed in this study for the first time. To the best of our knowledge, the AR inhibitory activities of thistles were also first displayed in the present work. The differences in the RLAR and HRAR inhibitory potency of two flavonoids might be attributed to the chemical structures of the ARIs, as well as the differences of AR sources, such as the species, site, and tissue, leading to the different degrees of bulk tolerance for the various enzymes (Nishimura et al., 1991; Brownlee, 2001; Kador et al., 1980). Also there are several reports that some flavones exhibited a non-competitive AR

inhibition with DL-glyceraldehyde as the variable substrate (Okuda et al., 1982).

In other words, the larger the quantity of **1** and **2** in the extract and fractions from various thistle parts, the more effective the intensity of the antioxidant activities in the $ONOO^-$, total ROS, and ·OH assays, and the AR inhibitory activities in the RLAR and HRAR assays, supporting the findings that these two major flavonoids might be employed as key components for further characterization in the antioxidant and anti-diabetic complications potential of *C. maackii*.

In conclusion, comparative evaluation upon the AR inhibitory activities and HPLC quantitative analysis of *C. maackii* might be of use to the development of therapeutic or preventive agents for oxidative stress-related diabetic complications. Moreover, this plant is a rich source of **1** and **2**, taking crucial roles in its bioactivities of this thistle. Therefore, this Korean thistle might be utilized as a medicinal and alternative herb source with a vast range of bioactivities and two active flavonoids (**1** and **2**). In addition, our present results will pave the way of the guideline for the efficacy, as well as preparation, differentiation, and standardization of this medicinal thistle, in that the bioactivities of the respective parts of this plant were evaluated. Further investigations into the bioactivity of these natural flavonoids may prove useful in the prevention of a variety of radical-mediated injuries and pathological situations *in vivo*.

Conflict of interest

The authors declare that there are no conflicts of interest.

Acknowledgements

This work was financially supported by the Pukyong National University under the 2009 Post-Doc. Program, the Blue-Bio Industry RIC at Dong-Eui University as a RIC program of ITEP under MKE and Busan City, and the Korea Food and Drug Administration (09112KFDA802) in 2009. We thank Aging Tissue Bank for providing research resources.

References

Agrawal, P.K., 1989. Carbon-13 NMR of Flavonoids. Elsevier Science Publishers, The Netherlands. pp. 134, 320.

Azad, N., Rojanasakul, Y., Vallyathan, V., 2008. Inflammation and lung cancer: roles of reactive oxygen/nitrogen species. J. Toxicol. Environ. Health B Crit. Rev. 11, 1–15.

Blois, M.S., 1958. Antioxidant determination by the use of a stable free radical. Nature 181, 1199–1202.

Brownlee, M., 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813–820.

Chung, A.K., Kwon, H.C., Choi, S.Z., Min, Y.D., Lee, S.O., Lee, W.B., Yang, M.C., Lee, K.H., Nam, J.H., Kwak, J.H., Lee, K.R., 2002. Norisoprenoids from *Cirsium rhinoceros*. Kor. J. Pharmacogn. 33, 81–84.

Chung, S.S., Ho, E.C., Lam, K.S., Chung, S.K., 2003. Contribution of polyol pathway to diabetes-induced oxidative stress. J. Am. Soc. Nephrol. 14, S233–S236.

Detaille, D., Sanchez, C., Sanz, N., Lopez-Novoa, J.M., Leverve, X., El-Mir, M.Y., 2008. Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perifused rat hepatocytes. Life Sci. 82, 1070–1076.

Harborne, J.B., 1967. Comparative biochemistry of flavonoids-V. Luteolin 5-glucoside and its occurrence in the Umbelliferae. Phytochemistry 6, 1569–1573.

Hayman, S., Kinoshita, J.H., 1965. Isolation and properties of lens aldose reductase. J. Biol. Chem. 240, 877–882.

Iwashina, T., Ito, T., Ootani, S., 1989. Characterization and identification of 5-glucoside of flavones obtained from Japanese *Cirsium* species. Ann. Tsukuba. Bot. Gard. 8, 15–19.

Iwashina, T., Kadota, Y., Ito, T., Ootani, S., 1995. Foliar flavonoid composition in Japanese *Cirsium* species (compositae) and their chemotaxonomic significance. J. Jpn. Bot. 70, 280–290.

Jeong, D.M., Jung, H.A., Choi, J.S., 2008. Comparative antioxidant activity and HPLC profiles of some selected Korean thistles. Arch. Pharm. Res. 31, 28–33.

Jo, Y., Kim, M., Shin, M.H., Chung, H.Y., Jung, J.H., Im, K.S., 2006. Antioxidative phenolics from the fresh leaves of *Ternstroemia japonica*. J. Nat. Prod. 69, 1399–1403.

Jordon-Thaden, I.E., Louda, S.M., 2001. Chemistry of *Cirsium* and *Carduus*: a role in ecological risk assessment for biological control of weeds? Biochem. Syst. Ecol. 31, 1353–1396.

Jung, S.H., Lee, J.M., Lee, H.J., Kim, C.Y., Lee, E.H., Um, B.H., 2007. Aldose reductase and advanced glycation endproducts inhibitory effect of *Phyllostachys nigra*. Biol. Pharm. Bull. 30, 1569–1572.

Jung, H.A., Jung, Y.J., Yoon, N.Y., Jeong, D.M., Bae, H.J., Kim, D.W., Na, D.H., Choi, J.S., 2008a. Inhibitory effects of *Nelumbo nucifera* leaves on rat lens aldose reductase, advanced glycation end products formation, and oxidative stress. Food Chem. Toxicol. 46, 3818–3826.

Jung, H.A., Yoon, N.Y., Kang, S.S., Kim, Y.S., Choi, J.S., 2008b. Inhibitory activities of prenylated flavonoids from *Sophora flavescens* against aldose reductase and generation of advanced glycation endproducts. J. Pharm. Pharmacol. 60, 1227–1236.

Kador, P.F., Kinoshita, J.H., Tung, W.H., Chylack Jr., L.T., 1980. Differences in the susceptibility of various aldose reductases to inhibition II. Invest. Ophthalmol. Vis. Sci. 19, 980–982.

Kaneko, M., Bucciarelli, M., Hwang, Y.C., Lee, L., Yan, S.F., Schmidt, A.M., Ramasamy, R., 2005. Aldose reductase and AGE-RAGE pathway: key players in myocardial ischemic injury. Ann. NY. Acad. Sci. 1043, 702–709.

Kato, A., Minoshima, Y., Yamamoto, J., Adachi, I., Watson, A.A., Nash, R.J., 2008. Protective effects of dietary chamomile tea on diabetic complications. J. Agric. Food Chem. 56, 8206–8211.

Kim, J.G., 1997. Illustrated Natural Drugs Encyclopedia (color edition), vol. 1. Namsandang, Korea, p. 37.

Kim, J.S., Kwon, C.S., Son, K.H., 2000. Inhibition of α-glucosidase and amylase by luteolin, a flavonoid. Biosci. Biotechnol. Biochem. 64, 58–61.

Kim, E.Y., Jho, H.K., Kim, D.I., Rhyu, M.R., 2008. *Cirsium japonicum* elicits endothelium-dependent relaxation *via* histamine H(1)-receptor in rat thoracic aorta. J. Ethnopharmacol. 116, 223–227.

Kooy, N.W., Royall, J.A., Ischiropoulos, H., Beckman, J.S., 1994. Peroxynitrite-mediated oxidation of dihydrorhodamine 123. Free. Radic. Biol. Med. 16, 149–156.

Ku, K.L., Tsai, C.T., Chang, W.M., Shen, M.L., Wu, C.T., Liao, H.F., 2008. Hepatoprotective effect of *Cirsium arisanense* Kitamura in tacrine-treated hepatoma Hep 3B cells and C57BL mice. Am. J. Chin. Med. 36, 355–368.

Lebel, C.P., Bondy, S.C., 1990. Sensitive and rapid quantitation of oxygen reactive species formation in rat synaptosomes. Neurochem. Int. 17, 435–440.

Lee, Y.N., 2002. Flora of Korea. Kyohak Publishing Co. Ltd., Korea. p. 844.

Lee, B.L., Kwan, J.H., Zee, O.P., Yoo, S.J., 1994. Flavonoids from *Cirsium rhinoceros*. Arch. Pharm. Res. 17, 273–277.

Lim, H., Son, K.H., Chang, H.W., Bae, K., Kang, S.S., Kim, H.P., 2008. Anti-inflammatory activity of pectolinarigenin and pectolinarin isolated from *Cirsium chanroenicum*. Biol. Pharm. Bull. 31, 2063–2067.

Liu, S., Zhang, J., Li, D., Liu, W., Luo, X., Zhang, R., Li, L., Zhao, J., 2007. Anticancer activity and quantitative analysis of flavone of *Cirsium japonicum* DC. Nat. Prod. Res. 21, 915–922.

López-Lázaro, M., 2009. Distribution and biological activities of the flavonoid luteolin. Mini Rev. Med. Chem. 9, 31–59.

Manzanaro, S., Salva, J., de la Fuente, J.A., 2006. Phenolic marine natural products as aldose reductase inhibitors. J. Nat. Prod. 69, 1485–1487.

Matsuda, H., Cai, H., Kubo, M., Tosa, H., Iinuma, M., 1995. Study on anti-cataract drugs from natural sources. II. Effects of Buddlejae flos on *in vitro* aldose reductase activity. Biol. Pharm. Bull. 18, 463–466.

Matsuda, H., Morikawa, T., Toguchida, I., Yoshikawa, M., 2002. Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity. Chem. Pharm. Bull. 50, 788–795.

Nazaruk, J., Jakoniuk, P., 2005. Flavonoid composition and antimicrobial activity of *Cirsium rivulare* (Jacq.) All. Flowers J. Ethnopharmacol. 102, 208–212.

Nencini, C., Giorgi, G., Micheli, L., 2007. Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine 14, 129–135.

Nishimura, C., Yamaoka, T., Mizutani, M., Yamashita, K., Akera, T., Tanimoto, T., 1991. Purification and characterization of the recombinant human aldose reductase expressed in baculovirus system. Biochim. Biophys. Acta. 1078, 171–178.

Okuda, J., Miwa, I., Inagaki, K., Horie, T., Nakayama, M., 1982. Inhibition of aldose reductases from rat and bovine lenses by flavonoids. Biochem. Pharmacol. 31, 3807–3822.

Pacher, P., Obrosova, I.G., Mabley, J.G., Szabó, C., 2005. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr. Med. Chem. 12, 267–275.

Park, J.C., Hur, J.M., Park, J.G., Kim, S.C., Park, J.R., Choi, S.H., Choi, J.W., 2004a. Effects of methanol extract of *Cirsium japonicum* var. *ussuriense* and its principle, hispidulin-7-O-neohesperidoside on hepatic alcohol-metabolizing enzymes and lipid peroxidation in ethanol-treated rats. Phytother. Res. 18, 19–24.

Park, Y.H., Xu, X.R., Chiou, G.C.Y., 2004b. Structural requirements of flavonoids for increment of ocular blood flow in the rabbit and retinal function recovery in rat eyes. J. Ocul. Pharmacol. Ther. 20, 189–200.

Perez, G.R., Ramirez, L.M., Vargas, S.R., 2001. Effect of *Cirsium pascuarense* on blood glucose levels of normoglycaemic and alloxan-diabetic mice. Phytother. Res. 15, 552–554.

Pradhan, S.C., Girish, C., 2006. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J. Med. Res. 124, 491–504.

Reddy, S.V., Tiwari, A.K., Kumar, U.S., Rao, R.J., Rao, J.M., 2005. Free radical scavenging, enzyme inhibitory constituents from antidiabetic Ayurvedic medicinal plant *Hydnocarpus wightiana* Blume. Phytother. Res. 19, 277–281.

Rice-Evans, C.A., Miller, N., Paganga, G., 1996. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med. 20, 933–956.

Singh, R.P., Agarwal, R., 2004. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutat. Res. 555, 21–32.

Srivastava, S.K., Ramana, K.V., Bhatnagar, A., 2005. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr. Rev. 26, 380–392.

Velussi, M., Cernigoi, A.M., De Monte, A., Dapas, F., Caffau, C., Zilli, M., 1997. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J. Hepatol. 26, 871–879.

Wallace, S., Vaughn, K., Stewart, B.W., Viswanathan, T., Clausen, E., Nagarajan, S., Carrier, D.J., 2008. Milk thistle extracts inhibit the oxidation of low-density lipoprotein (LDL) and subsequent scavenger receptor-dependent monocyte adhesion. J. Agric. Food Chem. 56, 3966–3972.

Wu, J.W., Lin, L.C., Tsai, T.H., 2009. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J. Ethnopharmacol. 121, 185–193.

Yim, S.H., Kim, H.J., Lee, I.S., 2003. A polyacetylene and flavonoids from *Cirsium rhinoceros*. Arch. Pharm. Res. 26, 128–131.

Yoo, Y.M., Nam, J.H., Kim, M.Y., Choi, J., Park, H.J., 2008. Pectolinarin and pectolinarigenin of *Cirsium setidens* prevent the hepatic injury in rats caused by d-galactosamine *via* an antioxidant mechanism. Biol. Pharm. Bull. 31, 760–764.

Zarzuelo, A., Jiménez, I., Gámez, M.J., Utrilla, P., Fernadez, I., Torres, M.I., Osuna, I., 1996. Effects of luteolin 5-O-β-rutinoside in streptozotocin-induced diabetic rats. Life Sci. 58, 2311–2316.